Vkt Pharma Company Profile
What is the competitive landscape for VKT PHARMA
VKT PHARMA has six approved drugs.
Drugs and US Patents for Vkt Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vkt Pharma | SUMATRIPTAN SUCCINATE | sumatriptan succinate | TABLET;ORAL | 219036-003 | Dec 31, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Vkt Pharma | TADALAFIL | tadalafil | TABLET;ORAL | 215556-001 | Nov 4, 2021 | AB1 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Vkt Pharma | SUMATRIPTAN SUCCINATE | sumatriptan succinate | TABLET;ORAL | 219036-002 | Dec 31, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Vkt Pharma | SUMATRIPTAN SUCCINATE | sumatriptan succinate | TABLET;ORAL | 219036-001 | Dec 31, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Vkt Pharma | RANOLAZINE | ranolazine | TABLET, EXTENDED RELEASE;ORAL | 214035-002 | Jan 19, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Vkt Pharma | TADALAFIL | tadalafil | TABLET;ORAL | 215556-003 | Nov 4, 2021 | AB1 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

